Archil Jaliashvili: World-First Use of HBOC-201 in a Double Organ Transplant Patient
Archil Jaliashvili, Co-owner, General Manager of SkinAI, Co-Chief Executive Officer at GeoBio Pharm, shared a post on LinkedIn about a recent article by M F Gomez et al, adding:
“World first: Used in a Double Organ Transplant Patient
A case that forces us to rethink oxygen delivery in modern medicine.
A 46-year-old kidney–pancreas transplant recipient ( Jehovah’s Witnesses) developed critical postoperative anemia.
Hemoglobin dropped to 2.0 g/dL.
At this level, mortality approaches near certainty.
Blood transfusion? Not possible.
The solution:
Compassionate use of HBOC-201 .
- 12 units infused over 8 days
Outcome
- Hemoglobin increased from 2.0 to 6.8 g/dL
- Patient extubated and discharged
- Both grafts functioning normally
- No liver, kidney, or pancreatic injury
30-Day follow-up results (From the Article)
Patient Status at 30 Days Post-Transplant:
- The patient continued to do well at 30 days after transplant (direct quote from the article)
Graft Function:
- Both transplanted organs (kidney and pancreas) were functioning normally – No signs of rejection or graft dysfunction
Kidney Function:
- Creatinine normalized to 0.8 mg/dL (excellent kidney function)
No any other Organ Damage.
- Patient was discharged home on POD 29
Result: This patient achieved 100% success at 30 days despite the life-threatening anemia
- Additionally why this matters for transplant medicine
HBOCs may solve several long-standing problems:
- No cell membranes – no antigens, no alloimmunization
- No lymphocytes – no GVHD risk
- Preserves future transplant options
- Acts as an oxygen bridge until erythropoiesis recovers
- Enables surgery for patients refusing blood transfusion
- More efficient microvascular oxygen delivery
Side effects were manageable
- Hypertension- controlled with nicardipine
- Methemoglobinemia – treated with methylene blue
Օther Evidence
- Animal models show 85% survival with HBOC vs 14% without product .
- Early clinical experiences suggest timely oxygen carrier support can be lifesaving.
What really dos it means, above real super results
With oxygenation organ was restore, we can assume that in so deep Anemia, was for sure injury!
One strategic suggestion:
This case suggests that oxygen therapeutics may become a strategic tool in transplant surgery, critical care, and bloodless medicine.
BHOC – Biological Hemoglobin Oxygen Carrier
We believe yes ! And what you think ? Share your opinion,story !”
Title: Hemoglobin-Based Oxygen Carrier Rescues Double-Transplant Patient From Life-Threatening Anemia
Authors: M F Gomez, O Aljure, G Ciancio, M Lynn
Read the Full Article on American Journal of Transplantation
Other posts featuring Archil Jaliashvili Hemostasis Today.
-
Mar 11, 2026, 15:46Bleeding and Thrombosis Outcomes in Older Patients With Myelodysplastic Syndromes – JTH
-
Mar 11, 2026, 15:37Sonia Muliyil: The Greatest Benefit is The Wellbeing and Sustenance of Half The World’s Population
-
Mar 11, 2026, 15:34Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
-
Mar 11, 2026, 15:34Sheharyar Raza: When More Testing Isn’t Always Better in Healthy Donor Screening
-
Mar 11, 2026, 15:26Maria Τektonidou: TMN Manifestation Scores and Mortality in Antiphospholipid Syndrome
-
Mar 11, 2026, 15:24Calum Robb: A Simplified Flow Cytometry Method for Measuring Human NETs
-
Mar 11, 2026, 15:19Sharmila Manian: Why Color-Coding is a Lifesaver in Patient Blood Management
-
Mar 11, 2026, 15:10Carlos Andrés Vergara Sánchez: Insights From the POLY-ACS Trial on Post-ACS Medication Adherence
-
Mar 11, 2026, 15:03Abdul Mannan: Why Early Recognition of APML-Associated DIC Saves Lives